BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smigiel JM, Parameswaran N, Jackson MW. Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Cancers (Basel) 2018;10:E14. [PMID: 29320425 DOI: 10.3390/cancers10010014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Du J, He Y, Wu W, Li P, Chen Y, Hu Z, Han Y. Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer. J Pharm Pharmacol 2019;71:196-205. [PMID: 30604411 DOI: 10.1111/jphp.12941] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
2 Pook H, Pauklin S. Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:4834. [PMID: 34638318 DOI: 10.3390/cancers13194834] [Reference Citation Analysis]
3 Olson JL, Bold RJ. Currently available first-line drug therapies for treating pancreatic cancer. Expert Opin Pharmacother 2018;19:1927-40. [PMID: 30325679 DOI: 10.1080/14656566.2018.1509954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Tawfik D, Zaccagnino A, Bernt A, Szczepanowski M, Klapper W, Schwab A, Kalthoff H, Trauzold A. The A818-6 system as an in-vitro model for studying the role of the transportome in pancreatic cancer. BMC Cancer 2020;20:264. [PMID: 32228510 DOI: 10.1186/s12885-020-06773-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Forciniti S, Dalla Pozza E, Greco MR, Amaral Carvalho TM, Rolando B, Ambrosini G, Carmona-Carmona CA, Pacchiana R, Di Molfetta D, Donadelli M, Arpicco S, Palmieri M, Reshkin SJ, Dando I, Cardone RA. Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine. Int J Mol Sci 2020;22:E29. [PMID: 33375106 DOI: 10.3390/ijms22010029] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zahan T, Das PK, Akter SF, Habib R, Rahman MH, Karim MR, Islam F. Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives. Anticancer Agents Med Chem 2020;20:2190-206. [PMID: 32748758 DOI: 10.2174/1871520620999200730161829] [Reference Citation Analysis]
7 Kamble SC, Sen A, Dhake RD, Joshi AN, Midha D, Bapat SA. Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers. J Clin Med 2019;8:E330. [PMID: 30857227 DOI: 10.3390/jcm8030330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Gilles ME, Hao L, Brown K, Lim J, Bhatia SN, Slack FJ. Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer. Oncotarget 2019;10:5349-58. [PMID: 31523393 DOI: 10.18632/oncotarget.27160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
9 Li J, Betzler C, Lohneis P, Popp MC, Qin J, Kalinski T, Wartmann T, Bruns CJ, Zhao Y, Popp FC. The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer. Int J Mol Sci 2020;21:E2215. [PMID: 32210079 DOI: 10.3390/ijms21062215] [Reference Citation Analysis]
10 Siregar P, Julen N, Hufnagl P, Mutter GL. Computational morphogenesis – Embryogenesis, cancer research and digital pathology. Biosystems 2018;169-170:40-54. [DOI: 10.1016/j.biosystems.2018.05.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
11 Parameswaran N, Bartel CA, Hernandez-Sanchez W, Miskimen KL, Smigiel JM, Khalil AM, Jackson MW. A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas. Sci Rep 2019;9:13396. [PMID: 31527715 DOI: 10.1038/s41598-019-49475-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Aydemİr Çoban E, Tecİmel D, KaŞikci E, Bayrak ÖF, Şahİn F. E-cadherin might be a stage-dependent modulator in aggressiveness in pancreatic cancer cells. Turk J Biol 2020;44:230-7. [PMID: 33110361 DOI: 10.3906/biy-1912-60] [Reference Citation Analysis]
13 Truong LH, Pauklin S. Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. Cancers (Basel) 2021;13:5028. [PMID: 34638513 DOI: 10.3390/cancers13195028] [Reference Citation Analysis]
14 Mu Z, Dong D, Wei N, Sun M, Wang W, Shao Y, Gao J, Yin P, Zhao C. Silencing of lncRNA AFAP1-AS1 Inhibits Cell Growth and Metastasis in Clear Cell Renal Cell Carcinoma. Oncol Res 2019;27:653-61. [PMID: 30832752 DOI: 10.3727/096504018X15420748671075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
15 Hermann PC, Sainz B Jr. Pancreatic cancer stem cells: A state or an entity? Semin Cancer Biol 2018;53:223-31. [PMID: 30130664 DOI: 10.1016/j.semcancer.2018.08.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
16 Stoica A, Chang C, Pauklin S. Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells. Trends in Pharmacological Sciences 2020;41:977-93. [DOI: 10.1016/j.tips.2020.09.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Das PK, Pillai S, Rakib MA, Khanam JA, Gopalan V, Lam AKY, Islam F. Plasticity of Cancer Stem Cell: Origin and Role in Disease Progression and Therapy Resistance. Stem Cell Rev Rep 2020;16:397-412. [PMID: 31965409 DOI: 10.1007/s12015-019-09942-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
18 Klemke L, Fehlau CF, Winkler N, Toboll F, Singh SK, Moll UM, Schulz-Heddergott R. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells. Front Oncol 2021;11:642603. [PMID: 34178628 DOI: 10.3389/fonc.2021.642603] [Reference Citation Analysis]
19 Gu Y, Ji Y, Jiang H, Qiu G. Clinical Effect of Driver Mutations of KRAS, CDKN2A/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis. Genet Test Mol Biomarkers 2020;24:777-88. [PMID: 33347393 DOI: 10.1089/gtmb.2020.0078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]